NVO’s Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults with type II diabetes (T2D).   This approval makes Rybelsus the first and only oral GLP-1 therapy approved to lower the risk of major adverse cardiovascular events (MACE), […]

American Airlines Drops Ozempic Coverage, Flight Attendants Push Back

Ozempic may still be flying high in America, but not in American Airlines’ employee health plan. American Airlines Cuts Ozempic From Flight Attendant Healthcare Coverage Starting January 1, 2026, American Airlines flight attendants will lose insurance coverage for popular GLP-1 medications such as Ozempic and Mounjaro, unless they have a formal diagnosis of Type 2 […]

Did Eli Lilly Just Say “Checkmate” to Novo Nordisk?

Key Points Though Novo Nordisk had a first-mover advantage in the GLP-1 market, Eli Lilly is catching up. Lilly’s recent clinical progress sets it up for another critical approval. The company has fantastic medium-term prospects. 10 stocks we like better than Eli Lilly › Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, was a pioneer in […]